

Contents

Preface XVII

List of Contributors XIX

1	A Chemist's Survey of Different Antibiotic Classes	1
	<i>Sonia Ilaria Maffioli</i>	
1.1	Introduction	1
1.2	Aminoglycosides	1
1.3	β -Lactams	3
1.4	Linear Peptides	4
1.4.1	Glycopeptides-Dalbaheptides	4
1.4.2	Lantibiotics	6
1.5	Cyclic Peptides	8
1.6	Thiazolylpeptides	11
1.7	Macrolactones	13
1.7.1	Macrolides	13
1.7.2	Difimicin	15
1.8	Ansamycins-Rifamycins	15
1.9	Tetracyclines	16
1.10	Oxazolidinones	16
1.11	Lincosamides	18
1.12	Pleuromutilins	18
1.13	Quinolones	19
1.14	Aminocoumarins	19
	References	20
2	Antibacterial Discovery: Problems and Possibilities	23
	<i>Lynn L. Silver</i>	
2.1	Introduction	23
2.2	Why Is Antibacterial Discovery Difficult? The Problems	24
2.3	Target Choice: Essentiality	24
2.4	Target Choice: Resistance	26
2.5	Cell Entry	31

2.6	Screening Strategies	32
2.6.1	Empirical Screens	32
2.6.2	Phenotypic Whole-Cell Screens	34
2.6.3	<i>In Vitro</i> Screens for Single-Target Inhibitors	37
2.6.4	Chemicals to Screen	38
2.6.4.1	Chemical Collections	38
2.7	Natural Products	40
2.8	Computational Chemistry, Virtual Screening, Structure- and Fragment-Based Drug Design (SBDD and FBDD)	42
2.9	Conclusions	45
	References	46
3	Impact of Microbial Natural Products on Antibacterial Drug Discovery	53
	<i>Gabriella Molinari</i>	
3.1	Introduction	53
3.2	Natural Products for Drug Discovery	54
3.3	Microbial Natural Products	56
3.4	The Challenge of Finding Novel Antibiotics from New Natural Sources	59
3.5	Workflow for Drug Discovery from Microbial Natural Products	60
3.6	Antimicrobial Activities: Targets for Screens	63
3.7	Natural Products: A Continuing Source for Inspiration	65
3.8	Genome Mining in Natural Product Discovery	66
3.9	Conclusions	67
	References	68
4	Antibiotics and Resistance: A Fatal Attraction	73
	<i>Giuseppe Gallo and Anna Maria Puglia</i>	
4.1	To Be or Not to Be Resistant: Why and How Antibiotic Resistance Mechanisms Develop and Spread among Bacteria	73
4.1.1	Horizontal and Vertical Transmission of Resistance Genes	74
4.2	Bacterial Resistance to Antibiotics by Enzymatic Degradation or Modification	79
4.2.1	Antibiotic Resistance by Hydrolytic Enzymes	80
4.2.1.1	β -Lactamases	81
4.2.1.2	Macrolide Esterases	81
4.2.1.3	Epoxidases	81
4.2.1.4	Proteases	83
4.2.2	Antibiotic Transferases Prevent Target Recognition	83
4.2.2.1	Acytransfer	83
4.2.2.2	Phosphotransferases	84
4.2.2.3	Nucleotidyltransferases	85
4.2.2.4	ADP-Ribosyltransferases	85
4.2.2.5	Glycosyltransferases	85

4.2.3	Redox Enzymes	86
4.3	Antibiotic Target Alteration: The Trick Exists and It Is in the Genetics	86
4.3.1	Low-Affinity Homologous Genes	86
4.3.1.1	Rifamycin Low-Affinity RpoB	87
4.3.1.2	Mutated Genes Conferring Resistance to Quinolone, Fluoroquinolone and Aminocoumarins	87
4.3.1.3	PBP2a: A Low-Affinity Penicillin-Binding Protein	87
4.3.1.4	Dihydropteroate Synthases Not Inhibited by Sulfonamide	88
4.3.2	Chemical Modification of Antibiotic Target	88
4.3.2.1	23S rRNA Modification	88
4.3.2.2	16S rRNA Modification	88
4.3.2.3	Reprogramming Chemical Composition of a Bacterial Cell-Wall Precursor	89
4.3.3	Ribosomal Protection and Tetracycline Resistance	89
4.3.4	Chromosomal Mutations in Genes Required for Membrane Phospholipid Metabolism: Lipopeptide Resistance	91
4.3.5	Covalent Modifications on Lipopolysaccharide Core Conferring Polymyxine Resistance	92
4.4	Efflux Systems	92
4.4.1	The ATP-Binding Cassette (ABC) Superfamily	94
4.4.2	The Major Facilitator Superfamily (MSF)	94
4.4.3	The Small Multidrug-Resistance Family (SMR)	96
4.4.4	The Resistance-Nodulation-Division (RND) Superfamily	96
4.4.5	The Multidrug and Toxic Compound Extrusion (MATE) Family	97
4.5	The Case Stories of Intrinsic and Acquired Resistances	98
4.5.1	β -Lactam Resistance of <i>P. aeruginosa</i> : Intrinsic Resistance Is Genetically Determined	98
4.5.2	Acquired Antibiotic Resistance in <i>S. aureus</i>	98
4.5.2.1	Acquired Resistance to β -Lactams and Glycopeptides	99
4.5.2.2	Acquired Resistance to Fluoroquinolones	100
4.6	Strategies to Overcome Resistance	100
	References	101
5	Fitness Costs of Antibiotic Resistance	109
	<i>Pietro Alifano</i>	
5.1	Introduction	109
5.2	Methods to Estimate Fitness	110
5.2.1	Experimental Methods	110
5.2.2	Epidemiological Methods	111
5.3	Factors Affecting Fitness	112
5.3.1	Genetic Nature of the Resistant Determinant	112
5.3.2	Expression of the Antibiotic-Resistance Determinant	118
5.3.3	Microbial Cell Physiology, Metabolism, and Lifestyle	119
5.3.4	Genetic Background of the Antibiotic-Resistant Mutant	120

5.4	Mechanisms and Dynamics Causing Persistence of Chromosomal and Plasmid-Borne Resistance Determinants	121
5.4.1	Compensatory Genetic Mechanisms That Restore or Improve Fitness without Loss of Resistance	121
5.4.2	Linked Selection and Segregation Stability of Resistance Determinants	126
5.4.3	Reacquisition of Antimicrobial Resistance	127
	References	128
6	Inhibitors of Cell-Wall Synthesis	133
	<i>Stefano Donadio and Margherita Sosio</i>	
6.1	Introduction	133
6.2	MraY Inhibitors	134
6.3	Lipid II Targeting Compounds	137
6.3.1	Glycopeptides	137
6.3.2	Lantibiotics	139
6.3.3	Ramoplanin and Enduracidin	143
6.3.4	Other Compounds	143
6.4	Bactoprenol Phosphate	145
6.5	Conclusions	146
	Acknowledgments	146
	References	147
7	Inhibitors of Bacterial Cell Partitioning	151
	<i>Bhavya Jindal, Anusri Bhattacharya, and Dulal Panda</i>	
7.1	Introduction	151
7.2	Bacterial Cell Division	152
7.2.1	Filamentous Temperature-Sensitive Z (FtsZ)	152
7.2.2	Structure and Assembly Properties of FtsZ	152
7.2.3	Z-Ring: A Dynamic Structure That Drives Bacterial Cell Division	153
7.2.4	Proteins Regulating FtsZ Assembly	155
7.2.5	Proteins Involved in Septum Formation	156
7.2.6	Role of Other Cytoskeleton Proteins in Bacterial Cell Division	157
7.3	Cell Division Proteins as Therapeutic Targets	158
7.3.1	FtsZ as a Therapeutic Target	158
7.3.1.1	Identification of FtsZ-Targeting Antibacterial Agents	158
7.3.1.2	FtsZ Inhibitors	161
7.3.2	Other Cell Division Proteins as Therapeutic Targets	170
7.4	Status of FtsZ-Targeting Compounds: From Laboratory to Clinic	172
7.5	Conclusion	173
	Acknowledgment	173
	Abbreviations	173
	References	174

8	The Membrane as a Novel Target Site for Antibiotics to Kill Persisting Bacterial Pathogens	183
	<i>Xiaoqian Wu and Julian G. Hurdle</i>	
8.1	Introduction	183
8.2	The Challenge of Treating Dormant Infections	184
8.3	Discovery Strategies to Prevent or Kill Dormant Bacteria	185
8.4	Why Targeting the Membrane Could Be a Suitable Strategy	186
8.5	Target Essentiality and Selectivity	186
8.6	Multiple Modes of Actions	188
8.6.1	Bactericidal and Low Potential for Resistance Development	189
8.7	Therapeutic Use of Membrane-Damaging Agents against Biofilms	190
8.8	New Approaches to Identifying Compounds That Kill Dormant Bacteria	196
8.9	Challenges for Biofilm Control with Membrane-Active Agents	196
8.9.1	Test Methods	197
8.9.2	Spectrum of Activity	197
8.9.3	Pharmacological	198
8.9.4	Genetic Resistance	199
8.10	Potential for Membrane-Damaging Agents in TB Disease	200
8.11	Application to Treatment of <i>Clostridium difficile</i> Infection	202
8.12	Is Inhibition of Fatty Acid/Phospholipid Biosynthesis Also an Approach?	203
8.13	Concluding Remarks	204
	References	204
9	Bacterial Membrane, a Key for Controlling Drug Influx and Efflux	217
	<i>Eric Valade, Anne Davin-Regli, Jean-Michel Bolla, and Jean-Marie Pagès</i>	
9.1	Introduction	217
9.2	The Mechanical Barrier	219
9.2.1	The Outer Membrane Barrier and Porin Involvement	219
9.2.2	Membrane Modification	221
9.2.3	Efflux Barrier	222
9.3	Circumventing the Bacterial Membrane Barrier	224
9.3.1	Increasing the Influx: Antibiotic plus Permeabilizer, "Increase I_n "	224
9.3.1.1	Permeabilizers such as Polymyxins	224
9.3.1.2	Natural Compounds	225
9.3.1.3	Silver Nanoparticles	225
9.3.2	Blocking the Efflux: Antibiotic plus Efflux Blocker, "Decrease E_{ef} "	225
9.3.2.1	The Chemical Response	226
9.3.2.2	Natural Products as Efflux Modulators	228
9.4	Conclusion	229
	Acknowledgments	231
	References	231

10	Interference with Bacterial Cell-to-Cell Chemical Signaling in Development of New Anti-Infectives	241
	<i>Jacqueline W. Njoroge and Vanessa Sperandio</i>	
10.1	Introduction	241
10.2	Two-Component Systems (TCSs) as Potential Anti-Infective Targets	242
10.3	Wak/WalR and MtrB/MtrA: Case Studies of Essential TCSs as Drug Targets	243
10.4	Targeting Nonessential TCS	246
10.4.1	QseC/QseB	248
10.4.2	AgrC/AgrA	248
10.4.3	FsrC/FsrA	249
10.4.4	PhoQ/PhoP	249
10.4.5	HrpX/HrpY	250
10.5	Non-TCSs Targeting Biofilm Formation and Quorum Sensing in <i>Pseudomonas</i> spp.	250
10.6	Conclusions	253
	References	254
11	Recent Developments in Inhibitors of Bacterial Type IIA Topoisomerases	263
	<i>Pan F. Chan, Jianzhong Huang, Benjamin D. Bax, and Michael N. Gwynn</i>	
11.1	Introduction	263
11.2	DNA-Gate Inhibitors	267
11.2.1	Quinolones and Related Compounds	267
11.2.1.1	Development of the Fluoroquinolone Class and Mechanism of Action	267
11.2.1.2	Phase 2 Fluoroquinolones	271
11.2.1.3	Quinazolidinediones ("Diones")	271
11.2.1.4	Isothiazolones	272
11.2.2	"NBTIs," Novel Bacterial Type II Topoisomerase Inhibitors	272
11.2.3	QPT (Quinoline Pyrimidine Trione)	274
11.2.4	Other DNA-Gate Inhibitors	275
11.2.4.1	Albicidin	275
11.2.4.2	Clerocidin	275
11.2.4.3	Nybmocin	275
11.2.4.4	Macromolecular Inhibitors That Stabilize Complexes with DNA	276
11.3	ATPase-Domain Inhibitors	276
11.3.1	Natural Products That Inhibit the ATPase Domain	276
11.3.1.1	Aminocoumarins	276
11.3.1.2	Cyclothialidines	280
11.3.1.3	Kibdelomycin and Amycolamicin	280
11.3.2	Recent GyrB and Dual-Targeting GyrB/ParE ATPase Inhibitors	281
11.3.2.1	Aminobenzimidazole Ureas	282
11.3.2.2	Imidazopyridines and Triazopyridines	282

11.3.2.3	Pyrrolopyrimidines and Pyrimidoindoles	283
11.3.2.4	Pyrazolthiazoles	283
11.3.2.5	Pyrrolamides	284
11.3.2.6	Clinical Progression of ATPase Inhibitors	284
11.4	Simocyclinones, Gyramides, and Other Miscellaneous Inhibitors	284
11.4.1	Simocyclinone D8	284
11.4.2	Gyramides	286
11.4.3	Other Miscellaneous Inhibitors	286
11.4.3.1	Pyrazoles	286
11.4.3.2	Quercetin Derivatives	286
11.4.3.3	Macromolecular Inhibitors of DNA Binding	286
11.5	Conclusions and Perspectives	287
	References	288
12	Antibiotics Targeting Bacterial RNA Polymerase	299
	<i>Konstantin Brodolin</i>	
12.1	Introduction	299
12.2	Antibiotics Blocking Nascent RNA Extension	304
12.2.1	Ansamycins (Rifamycins)	304
12.2.2	Sorangicin	306
12.3	Antibiotics Targeting RNAP Active Center	307
12.3.1	Streptolydigin and Other Acyl-Tetramic Acid Family Antibiotics	307
12.3.2	Lasso Peptides: Microcin j25 and Capistrin	308
12.3.3	CBR703 Series	309
12.4	Antibiotics Blocking Promoter Complex Formation	310
12.4.1	Myxopyronin	310
12.4.2	Corallopyronin	311
12.4.3	Ripostatin	311
12.4.4	Liparmycin	312
12.5	Inhibitors Hindering σ -Core Interactions	313
12.5.1	SB2 and Analogs (Phenyl-Furanyl-Rodanines)	313
12.6	Inhibitors with Unknown Mechanisms and Binding Sites	314
12.6.1	GE23077	314
12.6.2	Ureidothiophene	315
12.7	Conclusions and Perspectives	315
12.7.1	Bacterial RNA Polymerase Inhibitors are a Valid Source of Clinical Drugs	315
12.7.2	The σ Subunit of RNAP Modulates Antibiotics Activity	315
	References	316
13	Inhibitors Targeting Riboswitches and Ribozymes	323
	<i>Isabella Moll, Attilio Fabbretti, Letizia Brandi, and Claudio O. Gualerzi</i>	
13.1	Introduction	323
13.2	Riboswitches as Antibacterial Drug Targets	323
13.2.1	Purine Riboswitches	329

16.2.5	aaRSs as Targets for Antimicrobial Agents: General Modes of Inhibition	392
16.3	aaRS Inhibitors	393
16.3.1	Mupirocin, a Paradigm	393
16.3.2	Old and New Compounds with aaRS Inhibitory Activity	393
16.3.2.1	Natural Products That Inhibit aaRS	394
16.3.2.2	AaRS Inhibitors Identified in Screening Programs	397
16.3.3	Novel aaRS Inhibitors in Clinical Development	399
16.3.3.1	CRS3123, a Fully Synthetic MetRS Inhibitor	399
16.3.3.2	AN2690 (Tavorole) and AN3365 (GSK2251052), Boron-Containing LeuRS Inhibitors	401
16.4	Considerations for the Development of aaRS Inhibitors	403
16.4.1	Resistance Development	403
16.4.2	Selectivity over Eukaryotic and Mitochondrial Counterparts	404
16.4.3	Spectrum of Activity	404
16.4.4	Amino Acid Antagonism	404
16.5	Conclusions	405
	References	405
17	Antibiotics Targeting Translation Initiation in Prokaryotes	411
	<i>Cynthia L. Pon, Attilio Fabbretti, Letizia Brandi, and Claudio O. Gualerzi</i>	
17.1	Introduction	411
17.2	Mechanism of Translation Initiation	411
17.3	Inhibitors of Folate Metabolism	414
17.4	Methionyl-tRNA Formyltransferase	417
17.5	Inhibitors of Peptide Deformylase	417
17.6	Inhibitors of Translation Initiation Factor IF2	418
17.7	ppGpp Analogs as Potential Translation Initiation Inhibitors	422
17.8	Translation Initiation Inhibitors Targeting the P-Site	423
	References	429
18	Inhibitors of Bacterial Elongation Factor EF-Tu	437
	<i>Attilio Fabbretti, Anna Maria Giuliodori, and Letizia Brandi</i>	
18.1	Introduction	437
18.2	Enacyloxins	438
18.3	Kirromycin	444
18.4	Pulvomycin	446
18.5	GE2270A	448
	References	449
19	Aminoglycoside Antibiotics: Structural Decoding of Inhibitors Targeting the Ribosomal Decoding A Site	453
	<i>Jiro Kondo and Eric Westhof</i>	
19.1	Introduction	453
19.2	Chemical Structures of Aminoglycosides	455

19.3	Secondary Structures of the Target A Sites	455
19.4	Overview of the Molecular Recognition of Aminoglycosides by the Bacterial A Site	458
19.5	Role of Ring I: Specific Recognition of the Binding Pocket	459
19.6	Role of Ring II (2-DOS Ring): Locking the A-Site Switch in the "On" State	459
19.7	Dual Roles of Extra Rings: Improving the Binding Affinity and Eluding Defense Mechanisms	461
19.8	Binding of Semisynthetic Aminoglycosides to the Bacterial A Sites	463
19.9	Binding of Aminoglycosides to the Antibiotic-Resistant Bacterial Mutant and Protozoal Cytoplasmic A Sites	464
19.10	Binding of Aminoglycosides to the Human A Sites	464
19.11	Other Aminoglycosides Targeting the A Site but with Different Modes of Action	465
19.12	Aminoglycosides that Do Not Target the A Site	465
19.13	Nonaminoglycoside Antibiotic Targeting the A Site	466
19.14	Conclusions	466
	References	467
20	Peptidyltransferase Inhibitors of the Bacterial Ribosome	471
	<i>Daniel Wilson</i>	
20.1	Peptide Bond Formation and Its Inhibition by Antibiotics	471
20.2	Puromycin Mimics the CCA-End of tRNAs	472
20.3	Chloramphenicol Inhibit A-tRNA Binding in an Amino-Acid-Specific Manner	475
20.4	The Oxazolidinones Bind at the A-Site of the PTC	476
20.5	Lincosamide Action at the A-Site of the PTC	478
20.6	Blasticidin S Mimics the CCA-End of the P-tRNA at the PTC	478
20.7	Sparsomycin Prevents A-Site and Stimulates P-Site tRNA Binding	480
20.8	Pleuromutilins Overlap A- and P-Sites at the PTC	481
20.9	The Synergistic Action of Streptogramins at the PTC	483
20.10	Future Perspectives	484
	References	484
21	Antibiotics Inhibiting the Translocation Step of Protein Elongation on the Ribosome	491
	<i>Frank Peske and Wolfgang Wintermeyer</i>	
21.1	Introduction	491
21.2	Translocation: Overview	491
21.3	Antibiotics Inhibiting Translocation	494
21.3.1	Target: 30S Subunit, Decoding Site	494
21.3.2	Target: 30S Body	496
21.3.3	Target: 30S Subunit, Head Domain	496
21.3.4	Target: Intersubunit Bridge 2a	497
21.3.5	Target: 50S Subunit, GTPase-Associated Center	498

21.3.6	Target: EF-G	499
21.4	Antibiotics Inhibiting Translocation in Eukaryotes	500
21.4.1	Target: 40S Subunit, Decoding Site	500
21.4.2	Target: 60S Subunit, E Site	500
21.4.3	Target: eEF2	501
21.5	Antibiotics Inhibiting Ribosome Recycling in Bacteria	501
21.5.1	Target: Intersubunit Bridge 2a	502
21.5.2	Target: 50S Subunit, GTPase-Associated Center	503
21.5.3	Target: EF-G	503
21.6	Perspective	503
	References	504
22	Antibiotics at the Ribosomal Exit Tunnel—Selected Structural Aspects	509
	<i>Ella Zimmerman, Anat Bashan, and Ada Yonath</i>	
22.1	Introduction	509
22.2	The Multifunctional Tunnel	510
22.3	A Binding Pocket within the Multifunctional Tunnel	512
22.4	Remotely Resistance	513
22.5	Resistance Warfare	514
22.6	Synergism	515
22.7	Pathogen and “Patients” Models	517
22.8	Conclusion and Future Considerations	519
	Acknowledgments	519
	References	520
23	Targeting HSP70 to Fight Cancer and Bad Bugs: One and the Same Battle?	525
	<i>Jean-Hervé Alix</i>	
23.1	A Novel Target: The Bacterial Chaperone HSP70	525
23.2	An <i>In vivo</i> Screening for Compounds Targeting DnaK	528
23.3	Drugging HSP70	528
23.4	Cooperation between the Bacterial Molecular Chaperones DnaK and HtpG	530
23.5	Drugging HSP90	531
	References	532
	Index	539